Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Medicine | 11 | 2024 | 41 | 3.060 |
Why?
|
| Lung Neoplasms | 17 | 2023 | 712 | 2.410 |
Why?
|
| Bronchoscopy | 14 | 2022 | 88 | 2.290 |
Why?
|
| Tracheostomy | 4 | 2021 | 36 | 1.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 186 | 1.460 |
Why?
|
| Pleural Effusion | 2 | 2026 | 40 | 1.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2026 | 13 | 0.970 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 3 | 2020 | 12 | 0.960 |
Why?
|
| Pleurodesis | 4 | 2019 | 9 | 0.930 |
Why?
|
| Fibrinolytic Agents | 1 | 2026 | 183 | 0.870 |
Why?
|
| Respiratory Insufficiency | 2 | 2020 | 155 | 0.860 |
Why?
|
| Pleural Diseases | 2 | 2026 | 9 | 0.850 |
Why?
|
| Betacoronavirus | 3 | 2020 | 182 | 0.820 |
Why?
|
| Bronchoscopes | 2 | 2022 | 9 | 0.800 |
Why?
|
| Bronchial Diseases | 2 | 2022 | 13 | 0.800 |
Why?
|
| Tracheal Diseases | 2 | 2022 | 11 | 0.800 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2023 | 22 | 0.790 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 206 | 0.770 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 220 | 0.760 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2021 | 1665 | 0.720 |
Why?
|
| Needles | 2 | 2022 | 63 | 0.710 |
Why?
|
| Amyloidosis | 1 | 2022 | 70 | 0.680 |
Why?
|
| Pneumonia | 2 | 2021 | 295 | 0.660 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 327 | 0.630 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 6 | 0.610 |
Why?
|
| Physicians | 2 | 2023 | 486 | 0.570 |
Why?
|
| Education, Medical, Graduate | 5 | 2024 | 348 | 0.560 |
Why?
|
| Thoracoscopy | 4 | 2026 | 29 | 0.530 |
Why?
|
| Humans | 48 | 2026 | 65826 | 0.510 |
Why?
|
| Career Choice | 2 | 2020 | 129 | 0.510 |
Why?
|
| Clinical Competence | 8 | 2024 | 731 | 0.480 |
Why?
|
| Pleural Effusion, Malignant | 4 | 2019 | 12 | 0.460 |
Why?
|
| Pandemics | 4 | 2021 | 692 | 0.450 |
Why?
|
| Fellowships and Scholarships | 3 | 2024 | 103 | 0.450 |
Why?
|
| Mass Screening | 4 | 2015 | 700 | 0.430 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 117 | 0.410 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2022 | 16 | 0.390 |
Why?
|
| Catheters, Indwelling | 4 | 2018 | 67 | 0.380 |
Why?
|
| Accreditation | 3 | 2024 | 76 | 0.360 |
Why?
|
| Drainage | 2 | 2026 | 153 | 0.350 |
Why?
|
| Hypoxia | 1 | 2012 | 121 | 0.340 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 92 | 0.290 |
Why?
|
| Consensus | 2 | 2020 | 174 | 0.290 |
Why?
|
| Teaching | 1 | 2010 | 165 | 0.280 |
Why?
|
| United States | 9 | 2024 | 8190 | 0.250 |
Why?
|
| Patient Selection | 3 | 2020 | 484 | 0.250 |
Why?
|
| Societies, Medical | 5 | 2020 | 401 | 0.240 |
Why?
|
| Aged | 16 | 2026 | 15141 | 0.230 |
Why?
|
| Female | 21 | 2026 | 34414 | 0.220 |
Why?
|
| Lung | 2 | 2020 | 969 | 0.220 |
Why?
|
| Double-Blind Method | 1 | 2026 | 747 | 0.210 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 708 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2026 | 859 | 0.210 |
Why?
|
| Male | 21 | 2026 | 31398 | 0.210 |
Why?
|
| Hospitalization | 2 | 2021 | 1403 | 0.200 |
Why?
|
| Probability | 1 | 2023 | 170 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2026 | 5830 | 0.190 |
Why?
|
| Retrospective Studies | 11 | 2022 | 6953 | 0.190 |
Why?
|
| Middle Aged | 14 | 2026 | 18491 | 0.190 |
Why?
|
| Suction | 1 | 2022 | 34 | 0.180 |
Why?
|
| Bronchial Thermoplasty | 1 | 2021 | 1 | 0.180 |
Why?
|
| Mediastinum | 1 | 2022 | 28 | 0.180 |
Why?
|
| Talc | 2 | 2019 | 6 | 0.170 |
Why?
|
| Teacher Training | 1 | 2021 | 5 | 0.170 |
Why?
|
| Torsades de Pointes | 1 | 2021 | 6 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 20 | 0.170 |
Why?
|
| Clinical Protocols | 2 | 2020 | 138 | 0.170 |
Why?
|
| Learning Curve | 1 | 2021 | 33 | 0.170 |
Why?
|
| Vascular Calcification | 1 | 2021 | 27 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2022 | 237 | 0.160 |
Why?
|
| Pectoralis Muscles | 1 | 2020 | 8 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 319 | 0.160 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2020 | 1 | 0.160 |
Why?
|
| Emphysema | 1 | 2020 | 38 | 0.160 |
Why?
|
| Water | 1 | 2022 | 323 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 61 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 5681 | 0.150 |
Why?
|
| Smoking | 4 | 2014 | 864 | 0.150 |
Why?
|
| Silver Nitrate | 1 | 2019 | 1 | 0.150 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 5 | 0.150 |
Why?
|
| Tetracyclines | 1 | 2019 | 6 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2021 | 214 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.150 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 71 | 0.150 |
Why?
|
| Pneumothorax | 1 | 2019 | 49 | 0.150 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 109 | 0.140 |
Why?
|
| Hydrothorax | 1 | 2018 | 5 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 30 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 301 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 326 | 0.130 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 213 | 0.120 |
Why?
|
| Asthma | 1 | 2021 | 489 | 0.120 |
Why?
|
| Curriculum | 2 | 2020 | 609 | 0.120 |
Why?
|
| Mediastinal Neoplasms | 1 | 2016 | 21 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2016 | 33 | 0.110 |
Why?
|
| Lymphoma | 1 | 2016 | 101 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2790 | 0.110 |
Why?
|
| Adult | 6 | 2026 | 17567 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 12 | 0.100 |
Why?
|
| Anoikis | 1 | 2014 | 7 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 17 | 0.100 |
Why?
|
| Self-Assessment | 3 | 2020 | 60 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2015 | 183 | 0.100 |
Why?
|
| CD24 Antigen | 1 | 2013 | 18 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2020 | 901 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 42 | 0.100 |
Why?
|
| Sulindac | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2014 | 139 | 0.090 |
Why?
|
| Antigens, Surface | 1 | 2013 | 199 | 0.090 |
Why?
|
| Electromagnetic Phenomena | 1 | 2012 | 5 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 802 | 0.090 |
Why?
|
| Hematocrit | 1 | 2012 | 32 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2012 | 47 | 0.090 |
Why?
|
| Vital Capacity | 1 | 2012 | 123 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 81 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 286 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 367 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 526 | 0.090 |
Why?
|
| Anesthesia, Local | 1 | 2011 | 20 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 205 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 66 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2011 | 73 | 0.080 |
Why?
|
| Analgesia | 1 | 2011 | 37 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 202 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2018 | 1336 | 0.080 |
Why?
|
| Analgesics | 1 | 2011 | 102 | 0.080 |
Why?
|
| Educational Measurement | 1 | 2012 | 214 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 664 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 375 | 0.080 |
Why?
|
| Risk Factors | 4 | 2014 | 5471 | 0.080 |
Why?
|
| Career Mobility | 2 | 2020 | 65 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 502 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1146 | 0.070 |
Why?
|
| Palliative Care | 2 | 2018 | 251 | 0.070 |
Why?
|
| Tracheal Stenosis | 1 | 2008 | 9 | 0.070 |
Why?
|
| Faculty, Medical | 2 | 2023 | 202 | 0.070 |
Why?
|
| Benchmarking | 2 | 2023 | 137 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 603 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 645 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 808 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 1720 | 0.060 |
Why?
|
| Respiratory Mucosa | 1 | 2007 | 51 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 198 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 3339 | 0.060 |
Why?
|
| Bronchial Neoplasms | 1 | 2004 | 4 | 0.050 |
Why?
|
| Stents | 2 | 2009 | 501 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 23 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2004 | 38 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 1122 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2021 | 2649 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 588 | 0.050 |
Why?
|
| Bronchi | 2 | 2019 | 86 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2015 | 140 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 799 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 41 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 1267 | 0.040 |
Why?
|
| Massachusetts | 2 | 2020 | 2158 | 0.040 |
Why?
|
| Recurrence | 2 | 2017 | 665 | 0.040 |
Why?
|
| Citalopram | 1 | 2021 | 22 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 31 | 0.040 |
Why?
|
| Denmark | 1 | 2020 | 19 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 174 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 183 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 155 | 0.040 |
Why?
|
| Inhalation | 1 | 2019 | 11 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 82 | 0.040 |
Why?
|
| Incidence | 2 | 2014 | 1432 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2496 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 463 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 3778 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 154 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2021 | 223 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 556 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 199 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 142 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 184 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1595 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 222 | 0.030 |
Why?
|
| Deep Sedation | 1 | 2016 | 5 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hamartoma | 1 | 2015 | 12 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 579 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2015 | 21 | 0.030 |
Why?
|
| Granuloma | 1 | 2015 | 43 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2015 | 47 | 0.030 |
Why?
|
| Simulation Training | 1 | 2016 | 66 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 62 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2113 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 252 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 262 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2013 | 3 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 464 | 0.020 |
Why?
|
| North America | 1 | 2013 | 114 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2013 | 28 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 442 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 84 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 130 | 0.020 |
Why?
|
| Heterografts | 1 | 2013 | 67 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 199 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 167 | 0.020 |
Why?
|
| Interdisciplinary Studies | 1 | 2012 | 7 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 95 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2012 | 26 | 0.020 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 37 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2013 | 93 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 134 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 401 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 588 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 349 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 217 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1172 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 847 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 498 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 553 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 932 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 489 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1792 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1274 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 741 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 593 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 374 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 726 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 1029 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 297 | 0.010 |
Why?
|
| Prosthesis Fitting | 1 | 2004 | 7 | 0.010 |
Why?
|
| Hemoptysis | 1 | 2004 | 10 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 2004 | 24 | 0.010 |
Why?
|
| Device Removal | 1 | 2004 | 64 | 0.010 |
Why?
|
| Dyspnea | 1 | 2004 | 120 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2004 | 222 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 289 | 0.010 |
Why?
|
| Cough | 1 | 2004 | 183 | 0.010 |
Why?
|
| Biomarkers | 1 | 2007 | 1502 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 11185 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 21489 | 0.010 |
Why?
|